Boston Scientific stock receives consensus “buy” rating: 4 key notes

Analyst Ratings Network.com reported that Boston Scientific has received a consensus rating of “buy” from 24 research firms, according to WKRB News & Analysis.

Advertisement

Here are four key notes:

1. Boston Scientific has a 52-week low of $11.10 and a 52-week high of $18.62.

2. The average 12-month price objective among brokerages, which updated their coverage on the stock in the last year, is $19.03.

3. Boston Scientific’s 50-day moving average is $17.55 and its 200-day moving average is $17.29.

4. The company’s market capitalization is $23.61 billion.

More articles on GI/endoscopy:
Cape Regional Health System opens new endoscopy center: 3 things to know
Top 20 top-selling drugs in June
NJ Digestive Healthcare Center wins innovation award

At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.

Advertisement

Next Up in GI & Endoscopy

Advertisement

Comments are closed.